Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
Status:
Terminated
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
Our hypothesis is that treating ARDS caused by COVID-19 with bevacizumab improves mortality.
This is a phase II, multi-centered, randomized, open label, two-armed clinical trial to study
the safety and efficacy of bevacizumab in COVID-19 positive patients who consequently
developed ARDS (acute respiratory distress syndrome) and who have previously received
anti-viral and anti-inflammatory treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Maimónides Biomedical Research Institute of Córdoba